Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

UBT251

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

The United Bio-Technology (Hengqin) Co · Phase 2 · Recruiting · Enrollment 333

NCT07395687

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part A - UBT251n/rn/rn/rn/r
Part A - placebon/rn/rn/rn/r
Part B - Arm A (UBT251)n/rn/rn/rn/r
Part B - Arm B (UBT251)n/rn/rn/rn/r
Part B - Arm C (UBT251)n/rn/rn/rn/r
Part B - Arm D (UBT251)n/rn/rn/rn/r
Part B - Arm E (UBT251)n/rn/rn/rn/r
Part B - placebon/rn/rn/rn/r
Part C - UBT251 dose 1n/rn/rn/rn/r
Part C - UBT251 dose 2n/rn/rn/rn/r
Part C - UBT251 dose 3n/rn/rn/rn/r

Not shown

  • Part A - UBT251: endpoint not reported
  • Part A - placebo: endpoint not reported
  • Part B - Arm A (UBT251): endpoint not reported
  • Part B - Arm B (UBT251): endpoint not reported
  • Part B - Arm C (UBT251): endpoint not reported
  • Part B - Arm D (UBT251): endpoint not reported
  • Part B - Arm E (UBT251): endpoint not reported
  • Part B - placebo: endpoint not reported
  • Part C - UBT251 dose 1: endpoint not reported
  • Part C - UBT251 dose 2: endpoint not reported
  • Part C - UBT251 dose 3: endpoint not reported